Mepolizumab (Nucala) prior authorization at EmblemHealth
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
EmblemHealth requires prior-authorization documentation for Mepolizumab (Nucala): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
EmblemHealth reviews Mepolizumab (Nucala) prior authorizations against its medical policy . EmblemHealth-specific context: NY-based; operates HIP (HMO) and GHI (PPO) brands; ~3M members. Administers the NYC municipal employee GHI-CBP plan — high-volume source of OON disputes for retirees. NY DFS oversight; ConnectiCare is the Connecticut subsidiary.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- EmblemHealth's medical policy URL referenced in the cover letter
EmblemHealth's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- HIP HMO referral denials
- GHI PPO out-of-network reductions (NYC municipal employee plan)
- Behavioral health prior auth
- Specialty drug PA
Mepolizumab (Nucala)-specific denial patterns and context
Across payers (not just EmblemHealth), Mepolizumab (Nucala)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Eosinophil count threshold
- Step therapy requiring other biologics first
Brand: Nucala. IL-5 inhibitor for severe eosinophilic asthma + EGPA + HES.
Manufacturer patient-assistance program: Nucala Support Program — relevant when an EmblemHealth denial sticks and the patient needs bridge access while appealing.
If the PA is denied
EmblemHealth gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.emblemhealth.com/providers) with the same packet plus a peer-reviewed citation supporting Mepolizumab (Nucala)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an EmblemHealth denial on DenialHelp.
Contact EmblemHealth
- Provider portal: https://www.emblemhealth.com/providers
Frequently asked questions
What documentation does EmblemHealth need for Mepolizumab (Nucala) prior auth?
EmblemHealth's typical PA packet for Mepolizumab (Nucala): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at EmblemHealth?
Standard Mepolizumab (Nucala) PA decisions at EmblemHealth: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does EmblemHealth most often reject Mepolizumab (Nucala) for?
Across EmblemHealth's book the common rejection patterns include: HIP HMO referral denials; GHI PPO out-of-network reductions (NYC municipal employee plan); Behavioral health prior auth. For Mepolizumab (Nucala) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with EmblemHealth on Mepolizumab (Nucala)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Mepolizumab (Nucala) PA packet
Open ApprovalHelp — generate a Mepolizumab (Nucala) prior-auth packet tailored to EmblemHealth's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com